Alunbrig 90 mg (Brigatinib KIT) 90 MG

Alunbrig 90 mg is an oral medication used for targeted therapy in certain cancer treatments. This kit contains 7 tablets of 90 mg and 21 tablets of 180 mg, manufactured by Takeda Canada Inc.

Strength

90 MG

Pack Size

7X90MG/ 21X180MG

Manufacturer / TM Owner

TAKEDA CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Alunbrig 90 mg is primarily used in the treatment of specific types of cancer. It is designed to target and inhibit certain proteins that contribute to cancer cell growth. Patients often wonder, 'What is Alunbrig used for?' This medication is typically prescribed for advanced or metastatic non-small cell lung cancer with specific genetic markers.

Side Effects

Common effects of Alunbrig 90 mg may include nausea, fatigue, and muscle pain. Some users also report diarrhea and vomiting. These effects can vary widely among individuals, and it's important to consult a healthcare provider for personalized advice.

Precautions & Warnings

Alunbrig 90 mg should be handled with care and stored as directed. It is crucial to follow the prescribed dosage and administration instructions. Pregnant women or those planning to become pregnant should discuss the risks with their healthcare provider.

Avoid Interactions

Alunbrig 90 mg may interact with certain medications, including those that are metabolized by the liver. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and other substances may also affect the efficacy of this medication.

Frequently Asked Questions

Alunbrig is used in the treatment of specific types of cancer, particularly non-small cell lung cancer with certain genetic markers.

Alunbrig 90 mg is taken orally, typically as directed by a healthcare provider. Follow the prescribed dosage and administration instructions carefully.

Common side effects may include nausea, fatigue, muscle pain, diarrhea, and vomiting. Individual experiences can vary.

Alunbrig may interact with other medications, especially those metabolized by the liver. Consult your healthcare provider before combining with other treatments.

Pregnant women or those planning to become pregnant should discuss the risks with their healthcare provider before taking Alunbrig.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.